Comparison of Eletriptan and Zavegepant therapy in acute migraine: A literature review
1 Medical Study Program, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
2 Department of Anatomy, Histology and Pharmacology, Faculty of Medicine, Universitas Airlangga Surabaya, Indonesia.
Review Article
Magna Scientia Advanced Research and Reviews, 2025, 13(01), 001-007
Article DOI: 10.30574/msarr.2025.13.1.0234
Publication history:
Received on 23 November 2024; revised on 28 December 2024; accepted on 31 December 2024
Abstract:
Migraine is a genetically influenced headache characterized by a severe headache, usually affecting only one side and usually accompanied by nausea and sensitivity to light and sound. Migraine attacks can occur repeatedly and are triggered by several factors. Typically, migraine recurs several times a year during childhood and then progresses to several times a week during adulthood. The disease mostly affects people aged 22 to 55 years and can affect about 15% of the population in their productive years. Research regarding the comparison between eletriptan and zavegepant with acute migraine is still rarely known. Therefore, researchers are interested in conducting research on the comparison between eletriptan and zavegepant with acute migraine. This study is expected to be useful for enriching knowledge about the comparison between eletriptan and zavegepant with acute migraine in patients. However, further research is needed to directly compare the effectiveness of these two drugs in a wider and more diverse population.
Keywords:
Migraine; Eletriptan; Triptan; Zavegepant; Gepant
Full text article in PDF:
Copyright information:
Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0